Microsoft sued by Australia competition regulator over Copilot, 365 pricing
Investing.com - UBS has initiated coverage on IDEXX Laboratories (NASDAQ:IDXX) with a Neutral rating and a $720.00 price target, according to a research note released Wednesday. The stock, currently trading at $638.89, has shown remarkable strength with a 52.64% return over the past six months. According to InvestingPro analysis, IDEXX appears to be trading above its Fair Value.
UBS analyst Andrea Alfonso believes that current top-line estimates adequately account for IDEXX’s new cytology launches and international customer growth. With current revenue growth at 6.68% and a market capitalization of $51.11 billion, the firm notes that for consolidated revenue to return to historical growth ranges of 11% or higher, the company will need to rely less on price increases and more on veterinary visit growth. InvestingPro data reveals 16 additional key insights about IDEXX’s growth prospects.
The research indicates mixed adoption for IDEXX’s inVue analyzer, though UBS models suggest the product alone could drive a 1-2% annual contribution to growth on top of other growing platforms, providing multiple growth levers for the company.
Using UBS’s HOLT framework analysis, the firm concludes that IDEXX shares currently appear to be pricing in revenue deceleration to 9-10% from the 11% compound annual growth rate observed from 2015-2024.
The price target reflects UBS’s view that current market expectations appropriately balance macroeconomic risks against IDEXX’s attractive product pipeline.
In other recent news, IDEXX Laboratories reported impressive second-quarter results for 2025, exceeding both earnings and revenue forecasts. The company achieved an earnings per share (EPS) of $3.63, surpassing the expected $3.29, marking a 17% increase compared to the previous period. Revenue also outperformed projections, reaching $1.11 billion against a forecast of $1.06 billion. These strong results prompted Jefferies to raise its price target for IDEXX Laboratories from $625 to $785, while maintaining a Buy rating on the stock. Jefferies highlighted the company’s 10.6% sales growth and 14% EBITDA growth as key factors in their decision. These developments underscore the company’s robust performance in the recent quarter.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.